Program
trospium
Its studies are mostly in Alzheimer Disease · Schizophrenia · Mania · Autism Spectrum Disorder · Nausea, led by Bristol-Myers Squibb.
Furthest: phase 4, since Jun 26, 202621 company-led studies, 18 open or runningNext primary completion: Nov 24, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 2118 open or running | phase 4since Jun 26, 2026 | Aug 19, 2022 | Nov 24, 2026phase 3 · NCT06585787 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2022First study: phase 3 study in Psychosis Associated With Alzheimer's DiseaseFirst studyNCT05511363 · 410 planned · United States, Bulgaria, Croatia and more
- Jul 31, 2023Phase 3 study in Psychosis Associated With Alzheimer's DiseaseNCT05980949 · 1,000 planned · United States, Argentina, Belgium and more
- Nov 3, 2023Phase 3 study in Psychosis Associated With Alzheimer's DiseaseNCT06126224 · 500 planned · United States, Belgium, Canada and more
- Aug 8, 20242 phase 3 studiesNCT06572449, NCT06585787
- Sep 18, 2024Phase 1 study in Healthy VolunteersNCT06605950 · 78 enrolled · United States
- Feb 25, 2025Phase 1 study in Mental DisordersNCT06853171 · 24 enrolled · United States
- Mar 17, 2025Phase 3 study in SchizophreniaNCT06882785 · 250 planned · Japan
- Apr 14, 20255 phase 3 studiesNCT06929273, NCT06937229, NCT06951711 and 2 more
- May 9, 20252 phase 3 studies in Alzheimer DiseaseNCT06976216, NCT06976203
- Jul 2, 2025Phase 1 study in SchizophreniaNCT07061288 · 131 planned · United States
- Dec 9, 20253 phase 3 studiesNCT07284745, NCT07285798, NCT07288567
- Feb 13, 2026Phase 3 study in SchizophreniaNCT07424404 · 400 planned · United States, Australia, Canada and more
- Jun 26, 2026Phase 4 study in NauseaNCT07681076 · 180 planned · United States
Ahead
- Nov 1, 2026Primary completion: phase 3 study in ManiaNCT06951698
- Nov 2, 2026Primary completion: phase 3 study in ManiaNCT06951711
- Nov 24, 2026Primary completion: phase 3 study in Alzheimer DiseaseNCT06585787
- Nov 30, 2026Primary completion: phase 4 study in NauseaNCT07681076
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| trospium chloriderule | Bristol-Myers Squibb | phase 4 | 15 |
| Atropinerule | Laboratorios Sophia S.A de C.V. | phase 3 | 17 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07681076Nausea · United States | 4 | Recruiting | Nov 30, 2026 | 180 |
| NCT07424404Schizophrenia · United States, Australia, Canada and more | 3 | Recruiting | Mar 8, 2030 | 400 |
| NCT07288567Schizophrenia · United States, Colombia, Japan and more | 3 | Recruiting | Dec 18, 2029 | 166 |
| NCT07285798Autism Spectrum Disorder · United States, France, Germany and more | 3 | Recruiting | Aug 6, 2029 | 176 |
| NCT07284745Autism Spectrum Disorder · United States, Australia, Canada and more | 3 | Recruiting | Aug 6, 2029 | 176 |
| NCT07061288Schizophrenia · United States | 1 | Recruiting | Jun 21, 2027 | 131 |
| NCT06976216Alzheimer Disease · United States, Argentina, Australia and more | 3 | Recruiting | Sep 11, 2028 | 586 |
| NCT06976203Alzheimer Disease · United States, Argentina, Australia and more | 3 | Recruiting | Sep 11, 2028 | 586 |
| NCT06947941Alzheimer Disease · United States, Australia, Canada and more | 3 | Recruiting | Feb 21, 2028 | 325 |
| NCT06951711Mania · United States, China, Croatia and more | 3 | Recruiting | Nov 2, 2026 | 274 |
| NCT06951698Mania · United States, Argentina, Australia and more | 3 | Recruiting | Nov 1, 2026 | 274 |
| NCT06937229Alzheimer Disease · United States, Argentina, Brazil and more | 3 | Recruiting | Jun 22, 2029 | 650 |
| NCT06929273Mania · United States, Argentina, Australia and more | 3 | Recruiting | Jun 13, 2028 | 450 |
| NCT06882785Schizophrenia · Japan | 3 | Recruiting | Sep 23, 2028 | 250 |
| NCT06853171Mental Disorders · United States | 1 | Completed | Jul 22, 2025 | 24 |
| NCT06605950Healthy Volunteers · United States | 1 | Completed | May 31, 2025 | 78 |
| NCT06585787Alzheimer Disease · United States, Argentina, Belgium and more | 3 | Recruiting | Nov 24, 2026 | 406 |
| NCT06572449Schizophrenia · United States | 3 | Completed | Mar 13, 2025 | 173 |
| NCT06126224Psychosis Associated With Alzheimer's Disease · United States, Belgium, Canada and more | 3 | Recruiting | Dec 9, 2026 | 500 |
| NCT05980949Psychosis Associated With Alzheimer's Disease · United States, Argentina, Belgium and more | 3 | Recruiting | Sep 7, 2027 | 1,000 |
| NCT05511363Psychosis Associated With Alzheimer's Disease · United States, Bulgaria, Croatia and more | 3 | Recruiting | Oct 5, 2026 | 410 |
How it is read
Names in the registry
- “KarXT”, 21 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 8 studies
- Schizophrenia, 5 studies
- Mania, 3 studies
- Autism Spectrum Disorder, 2 studies
- Nausea, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.